Cargando…
Case Report: Molecular and microenvironment change upon midostaurin treatment in mast cell leukemia at single-cell level
Mast cell leukemia is a rare and aggressive disease, predominantly with KIT D816V mutation. With poor response to conventional poly-chemotherapy, mast cell leukemia responded to the midostaurin treatment with a 50% overall response rate (ORR), but complete remission rate is approximately 0%. Therefo...
Autores principales: | Liu, Meng-Ke, Liu, Feng, Dai, Yu-Ting, Weng, Xiang-Qin, Cheng, Li-Li, Fan, Li-Quan, Liu, Han, Jiang, Lu, Sun, Xiao-Jian, Fang, Hai, Wang, Li, Zhao, Wei-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449247/ https://www.ncbi.nlm.nih.gov/pubmed/37638009 http://dx.doi.org/10.3389/fimmu.2023.1210909 |
Ejemplares similares
-
Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018) -
Mast cells in colorectal cancer tumour progression, angiogenesis, and lymphangiogenesis
por: Liu, Xiaoxin, et al.
Publicado: (2023) -
Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
por: Lu, Hao, et al.
Publicado: (2022) -
Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016) -
Tryptase Regulates the Epigenetic Modification of Core Histones in Mast Cell Leukemia Cells
por: Alanazi, Sultan, et al.
Publicado: (2021)